When was Quartz Bio founded?

Quartz Bio was founded in 2012.

Where is Quartz Bio located?

Quartz Bio is headquartered in Geneva, Switzerland.

How many employees does Quartz Bio have?

As of Mar 31, 2026, the latest employee count at Quartz Bio is 62.

Is Quartz Bio a funded company?

Quartz Bio is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Quartz Bio rank among its competitors?

Quartz Bio ranks 1142nd amongst 1949 active competitors, of which 456 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Quartz Bio?

Quartz Bio's top competitors include Synthego, Sutro Biopharma and Avidity Biosciences. Among them, Antheia secured the most recent funding round in January, 2026.

Quartz Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Quartz Bio is a clinical bioinformatics and biostatistics services company that analyzes biomarker data from clinical trials for its clients, which include pharmaceutical and diagnostics companies. The company's service pipeline starts from the design of experiment to development of statistical analysis plan, followed by the analysis and patient stratification, visualizations and a detailed reporting. The company claims that its strength lies in exploratory data analysis, and in the design of experiments, generation of manual of operations for large exploratory studies to ensure proper data collection.

Website: www.quartz.bio/
Social
Email ID: *****@quartz.bio

Key Metrics

Founded Year

2012

Location

Geneva, Switzerland

Stage

Acquired

Investors

Fongit

Ranked

1142^nd among 1949 active competitors

Employee Count

62 as on Mar 31, 2026

Investment & Acquisitions

SolveBio

Similar Companies

Synthego & 2660 more

Exit Details

Acquired by Precision Medicine Group (Jan 10, 2018)

View Quartz Bio's full profile

Quartz Bio got acquired by Precision Medicine Group on Jan 10, 2018.

Click here to take a look at Quartz Bio's acquisition in detail

Quartz Bio is a funded company. Quartz Bio has 1 institutional investor.

View details of Quartz Bio's funding rounds and investors

The founders of Quartz Bio are Karl Forner, Alessandro Di Cara and Jerome Wojcik.

Here are the details of Quartz Bio's key team members:

Karl Forner: Co-Founder of Quartz Bio.
Alessandro Di Cara: Co-Founder of Quartz Bio.
Jerome Wojcik: Founder & CEO of Quartz Bio.

View details of Quartz Bio's Founder profiles and Board Members

Quartz Bio's employee count trend

Quartz Bio has 62 employees as of Mar 26. Here is Quartz Bio's employee count trend over the years:

Uncover Quartz Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Quartz Bio include Synthego, Sutro Biopharma and Avidity Biosciences. Here is the list of Top 10 competitors of Quartz Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
2nd	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	69/100
3rd	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 19 others	68/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Citadel, New Enterprise Associates & 14 others	67/100
5th	Savara Pharma 2008, Austin (United States), Public	Developer of therapeutics for rare respiratory diseases	$67.8M	Austin Technology Incubator, Logos & 19 others	67/100
6th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
7th	Engine Biosciences 2014, Singapore (Singapore), Series A	Developer of platform technology for combinatorial genetics discovery	$86M	Polaris Partners, DHVC & 18 others	66/100
8th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, China Structural Reform Fund ... & 11 others	66/100
9th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
10th	Invenra 2011, Madison (United States), Series A	Pioneering bispecific and trispecific antibody discovery and development for novel therapies	$21.3M	Venture Investors, Venture Management & 4 others	65/100
1142nd	Quartz Bio 2012, Geneva (Switzerland), Acquired	Bioinformatics services for biomarker analysis	-	Fongit	26/100